stockrow
Monday 2 November 2026
Export ARVN’s income statement to Excel — free account
Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.
- Revenue
- +1,014.7%
- EPS
- +410.7%
- Free cash flow
- +49.8%
- Total debt
- −40.0%
Quarter to June 2026, against a year earlier
7.56
0.30
−3.82%
Follow ARVN
Alert me
Arvinas, Inc. (ARVN) P/E ratio
As of 2 November 2026, Arvinas, Inc. (ARVN) trades at a P/E ratio of 39.5×. Over the past ten years it has ranged from 0.0× (June 2026) to 50.5× (August 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 12.4× and above the Healthcare sector median of 25.8×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 43.4× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 50.5×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| PHAT Phathom Pharmaceuticals, Inc. compare | n/m |
| OCS Oculis Holding AG compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| CBIO Crescent Biopharma, Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| OVID Ovid Therapeutics compare | n/m |
| CTMX CytomX Therapeutics, Inc. compare | n/m |
| ARVN Arvinas, Inc. | 39.5× |
| Biotechnology industry median | 12.4× |
| Healthcare sector median | 25.8× |
| Market median | 18.6× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)